At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 177 enrolled
Drug / intervention
Panitumumab +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Phase 1b/2 Trial of AMG 102 or AMG 479 in Combination With Panitumumab Versus Panitumumab Alone in Subject With Wild-Type KRAS Metastatic Colorectal Cancer
In Brief
A Phase 2 clinical trial evaluating Panitumumab, Ganitumab, and 2 other interventions for Colon Cancer and 4 related conditions. Completed, enrolled 177 participants.
Detailed Summary
This study is a global, multicenter, open-label phase 1b and randomized, double-blinded, 2 part, phase 2 study designed to evaluate the safety and efficacy of rilotumumab or ganitumab in combination with panitumumab versus panitumumab alone in patients with metastatic colorectal cancer whose tumors are wild-type KRAS status.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColon Cancer, Colorectal Cancer, Gastrointestinal Cancer, Metastatic Colorectal Cancer, Rectal Cancer
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2008
First PostedNov 2008
Primary CompletionJul 2010
TodayJul 2026
First PostedNov 11, 2008
Enrollment StartOct 27, 2008
Primary CompletionJul 23, 2010
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 17.6 years ago
Interventions
Panitumumabdrug
Panitumumab for intravenous infusion
Ganitumabdrug
Ganitumab for intravenous infusion
Rilotumumabdrug
Rilotumumab for intravenous infusion
Placebodrug
Placebo intravenous infusion